Clinical Trial Update: The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation [Phase 2]

View source ↗

Summary

This document reports a Phase 2 trial evaluating icotinib as perioperative therapy for EGFR-mutant stage IIIA-IIIB non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Beijing Haidian Hospital | Conditions: Non-small Cell Lung Cancer(NSCLC) | Phase 2 | Status: UNKNOWN